by Dan DeMarle | Oct 12, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment
“The U.S. Food and Drug Administration has approved Tris Pharma’s once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD). The once-a-day, extended-release, oral...
by Dan DeMarle | Oct 12, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Other Health Impairment
HealthDay News — Diagnoses of attention-deficit/hyperactivity disorder (ADHD) in U.S. children continue to increase, with approximately one in nine having ever received a diagnosis, according to a study published online May 23 in the Journal of Clinical Child &...
by Dan DeMarle | Sep 30, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Other Health Impairment
24-9-29 NCHS Data Brief Number 499 March 2024 – db499Download
by Dan DeMarle | Sep 4, 2024 | ADHD, Other Health Impairment
“A recent study published in Journal of Attention Disorders reveals that young people with attention-deficit/hyperactivity disorder (ADHD) experience significantly higher levels of loneliness than their peers, highlighting a critical aspect of the disorder that...
by Dan DeMarle | Aug 25, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Other Health Impairment, Recommended Reading
By Sari Solden Sari Solden specializes in working with ADD adults and their partners. Her first book, Women with Attention Deficit Disorder , has sold more than 100,000 copies worldwide. Now, in Journeys Through ADDulthood , she takes a groundbreaking look at the...
by Dan DeMarle | Aug 10, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Emotional Disturbance, Emotional regulation, Other Health Impairment
By understanding the science of ADHD and emotion dysregulation, psychologists can offer better support More and more teenagers and adults are turning to social media to share their experiences living with attention-deficit/hyperactivity disorder (ADHD). Amid that...
